JP6090855B2 - 心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法 - Google Patents

心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法 Download PDF

Info

Publication number
JP6090855B2
JP6090855B2 JP2013523110A JP2013523110A JP6090855B2 JP 6090855 B2 JP6090855 B2 JP 6090855B2 JP 2013523110 A JP2013523110 A JP 2013523110A JP 2013523110 A JP2013523110 A JP 2013523110A JP 6090855 B2 JP6090855 B2 JP 6090855B2
Authority
JP
Japan
Prior art keywords
cells
inhibitor
cardiomyocyte
myocardial progenitor
myocardial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013523110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544071A (ja
JP2013544071A5 (enExample
Inventor
山下　潤
潤 山下
英毅 魚崎
英毅 魚崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JP2013544071A publication Critical patent/JP2013544071A/ja
Publication of JP2013544071A5 publication Critical patent/JP2013544071A5/ja
Application granted granted Critical
Publication of JP6090855B2 publication Critical patent/JP6090855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013523110A 2010-11-17 2011-11-17 心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法 Expired - Fee Related JP6090855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41481210P 2010-11-17 2010-11-17
US61/414,812 2010-11-17
PCT/JP2011/077266 WO2012067266A1 (en) 2010-11-17 2011-11-17 Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells

Publications (3)

Publication Number Publication Date
JP2013544071A JP2013544071A (ja) 2013-12-12
JP2013544071A5 JP2013544071A5 (enExample) 2015-01-08
JP6090855B2 true JP6090855B2 (ja) 2017-03-08

Family

ID=46084181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523110A Expired - Fee Related JP6090855B2 (ja) 2010-11-17 2011-11-17 心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法

Country Status (4)

Country Link
US (1) US9074188B2 (enExample)
EP (1) EP2640829A4 (enExample)
JP (1) JP6090855B2 (enExample)
WO (1) WO2012067266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
WO2012133954A1 (en) * 2011-03-31 2012-10-04 Kyoto University Novel cardiomyocyte marker
WO2014025315A1 (en) * 2012-08-07 2014-02-13 Singapore Health Services Pte Ltd Method, combination and/or composition for inducing cardiomyocyte differentation
WO2014071323A2 (en) * 2012-11-02 2014-05-08 Duke University Inhibition of histone methyltransferase for cardiac reprogramming
WO2015119575A2 (en) * 2014-02-06 2015-08-13 Singapore Health Services Pte Ltd Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation
US10865384B2 (en) 2014-02-07 2020-12-15 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016154362A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
WO2017181166A1 (en) * 2016-04-15 2017-10-19 Temple University-Of The Commonwealth System Of Higher Education Microrna-294 and ln28a as a driver of cardiac tissue proliferation in response to pathological injury
WO2019006512A1 (en) * 2017-07-07 2019-01-10 The University Of Queensland REGENERATION OF CARDIOMYOCYTES
EP3765486A4 (en) * 2018-03-16 2022-03-02 The Board of Trustees of the Leland Stanford Junior University REAGENTS AND METHODS USING WNT AGONISTS AND BIOACTIVE LIPIDS FOR CARDIOMYOCYTE GENERATION AND EXPANSION
US12295930B2 (en) 2018-08-14 2025-05-13 Emory University Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
US20220187282A1 (en) * 2019-03-18 2022-06-16 The Council Of The Queensland Institute Of Medical Research Cardiomyocyte proliferation
EP4003515B1 (en) * 2019-07-30 2025-10-22 Victor Chang Cardiac Research Institute Klf induced cardiomyogenesis
WO2022006094A1 (en) * 2020-06-30 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University MOLECULES REGULATING HUMAN iPSC-DERIVED CARDIOMYOCYTES PROLIFERATION BY INHIBITING CELL-CELL CONTACT
CN112481200A (zh) * 2020-12-25 2021-03-12 扬州大学 一种提升大鼠骨髓间充质干细胞分化为心肌细胞效率的方法
CN120041570A (zh) * 2025-02-28 2025-05-27 太原理工大学 CaMKII-α抑制剂在制备治疗T细胞淋巴瘤的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
KR101169980B1 (ko) 2003-11-21 2012-07-31 다이이찌 산쿄 가부시키가이샤 심근 세포의 증식 방법
WO2006118914A2 (en) * 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
EP1910518B1 (en) 2005-06-22 2019-05-08 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
WO2007069666A1 (ja) 2005-12-13 2007-06-21 Kyoto University 核初期化因子
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2009118928A1 (en) 2008-03-26 2009-10-01 Kyoto University Efficient production and use of highly cardiogenic progenitors and cardiomyocytes from embryonic and induced pluripotent stem cells
JP2010158206A (ja) 2009-01-08 2010-07-22 National Institute Of Advanced Industrial Science & Technology ヒト心筋前駆細胞の選別方法

Also Published As

Publication number Publication date
US9074188B2 (en) 2015-07-07
JP2013544071A (ja) 2013-12-12
US20130244262A1 (en) 2013-09-19
EP2640829A1 (en) 2013-09-25
WO2012067266A1 (en) 2012-05-24
EP2640829A4 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
JP6090855B2 (ja) 心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法
JP7282304B2 (ja) 新規ドーパミン産生神経前駆細胞の誘導方法
JP6143268B2 (ja) ヒト多能性幹細胞から中間中胚葉細胞への分化誘導方法
JP5896360B2 (ja) ヒト多能性幹細胞から中間中胚葉細胞への分化誘導方法
KR102312123B1 (ko) 도파민 생산 신경전구세포의 제조방법
KR102219743B1 (ko) 신규 연골 세포 유도 방법
JP6143027B2 (ja) アストロサイトの誘導方法
US9796962B2 (en) Method for generating pancreatic hormone-producing cells
CN108138129A (zh) 血管内皮细胞的诱导方法
WO2016108288A1 (ja) 骨格筋前駆細胞の製造方法
JP7357369B2 (ja) 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
JP6780197B2 (ja) 新規成熟心筋細胞マーカー
CN121136933A (zh) 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170202

R150 Certificate of patent or registration of utility model

Ref document number: 6090855

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees